Leila Jalinous

Leila Jalinous is experienced in leading gene therapy strategy at CANbridge Pharmaceuticals Inc. Leila's background includes roles in strategy, program management, market access, and marketing at various pharmaceutical companies such as Alnylam Pharmaceuticals, Biogen Idec, Critical Therapeutics, and Genzyme. Leila holds a Master's degree in Health/Health Care Administration/Management from the University of Washington and a Bachelor's degree in Economics and Biology from Boston University.